411 related articles for article (PubMed ID: 33150497)
1. Rivaroxaban Versus Warfarin in Patients with Mechanical Heart Valves: Open-Label, Proof-of-Concept trial-The RIWA study.
Duraes AR; de Souza Lima Bitar Y; Schonhofen IS; Travassos KSO; Pereira LV; Filho JAL; Neto MG; Junior RA; Roever L
Am J Cardiovasc Drugs; 2021 May; 21(3):363-371. PubMed ID: 33150497
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study.
Durães AR; de Souza Lima Bitar Y; Filho JAL; Schonhofen IS; Camara EJN; Roever L; Cardoso HEDP; Akrami KM
Drugs R D; 2018 Dec; 18(4):303-308. PubMed ID: 30293126
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.
Guimarães HP; Lopes RD; de Barros E Silva PGM; Liporace IL; Sampaio RO; Tarasoutchi F; Hoffmann-Filho CR; de Lemos Soares Patriota R; Leiria TLL; Lamprea D; Precoma DB; Atik FA; Silveira FS; Farias FR; Barreto DO; Almeida AP; Zilli AC; de Souza Neto JD; Cavalcante MA; Figueira FAMS; Kojima FCS; Damiani L; Santos RHN; Valeis N; Campos VB; Saraiva JFK; Fonseca FH; Pinto IM; Magalhães CC; Ferreira JFM; Alexander JH; Pavanello R; Cavalcanti AB; Berwanger O;
N Engl J Med; 2020 Nov; 383(22):2117-2126. PubMed ID: 33196155
[TBL] [Abstract][Full Text] [Related]
4. A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial.
Guimarães HP; de Barros E Silva PGM; Liporace IL; Sampaio RO; Tarasoutchi F; Paixão M; Hoffmann-Filho CR; Patriota R; Leiria TLL; Lamprea D; Precoma DB; Atik FA; Silveira FS; Farias FR; Barreto DO; Almeida AP; Zilli AC; de Souza Neto JD; Cavalcante MA; Figueira FAMS; Junior RA; Moisés VA; Mesas CE; Ardito RV; Kalil PSA; Paiva MSMO; Maldonado JGA; de Lima CEB; D'Oliveira Vieira R; Laranjeira L; Kojima F; Damiani L; Nakagawa RH; Dos Santos JRY; Sampaio BS; Campos VB; Saraiva JFK; Fonseca FH; Pinto IM; Magalhães CC; Ferreira JFM; Lopes RD; Pavanello R; Cavalcanti AB; Berwanger O;
Am Heart J; 2021 Jan; 231():128-136. PubMed ID: 33045224
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
7. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.
Fordyce CB; Hellkamp AS; Lokhnygina Y; Lindner SM; Piccini JP; Becker RC; Berkowitz SD; Breithardt G; Fox KA; Mahaffey KW; Nessel CC; Singer DE; Patel MR;
Circulation; 2016 Jul; 134(1):37-47. PubMed ID: 27358435
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin After Bioprosthetic Valve Replacements.
Pasciolla S; Zizza LF; Le T; Wright K
Clin Drug Investig; 2020 Sep; 40(9):839-845. PubMed ID: 32607688
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.
Pengo V; Denas G; Zoppellaro G; Jose SP; Hoxha A; Ruffatti A; Andreoli L; Tincani A; Cenci C; Prisco D; Fierro T; Gresele P; Cafolla A; De Micheli V; Ghirarduzzi A; Tosetto A; Falanga A; Martinelli I; Testa S; Barcellona D; Gerosa M; Banzato A
Blood; 2018 Sep; 132(13):1365-1371. PubMed ID: 30002145
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
Signorelli JR; Gandhi AS
J Oncol Pharm Pract; 2019 Mar; 25(2):362-368. PubMed ID: 29157146
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
14. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
Patel MR; Mahaffey KW; Garg J; Pan G; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Piccini JP; Becker RC; Nessel CC; Paolini JF; Berkowitz SD; Fox KA; Califf RM;
N Engl J Med; 2011 Sep; 365(10):883-91. PubMed ID: 21830957
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
Perales IJ; San Agustin K; DeAngelo J; Campbell AM
Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
[No Abstract] [Full Text] [Related]
16. Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease.
Briasoulis A; Inampudi C; Akintoye E; Alvarez P; Panaich S; Vaughan-Sarrazin M
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622591
[TBL] [Abstract][Full Text] [Related]
17. Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin.
Coleman CI; Costa OS; Brescia CW; Vardar B; Abdelgawwad K; Sood N
Cardiovasc Diabetol; 2021 Feb; 20(1):52. PubMed ID: 33637082
[TBL] [Abstract][Full Text] [Related]
18. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.
Leef GC; Hellkamp AS; Patel MR; Becker RC; Berkowitz SD; Breithardt G; Halperin JL; Hankey GJ; Hacke W; Nessel CC; Singer DE; Fox KAA; Mahaffey KW; Piccini JP
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28615214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
